WINTON GROUP Ltd cut its holdings in Merck & Co., Inc. (NYSE:MRK) by 66.6% in the 2nd quarter, HoldingsChannel reports. The fund owned 6,540 shares of the company’s stock after selling 13,043 shares during the period. WINTON GROUP Ltd’s holdings in Merck & Co., Inc. were worth $509,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of MRK. Franklin Resources Inc. grew its position in shares of Merck & Co., Inc. by 20.6% in the first quarter. Franklin Resources Inc. now owns 35,455,780 shares of the company’s stock valued at $2,733,289,000 after purchasing an additional 6,063,098 shares during the period. LSV Asset Management boosted its stake in Merck & Co., Inc. by 47.8% in the 2nd quarter. LSV Asset Management now owns 14,306,091 shares of the company’s stock worth $1,112,584,000 after buying an additional 4,628,832 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Merck & Co., Inc. by 57.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,464,738 shares of the company’s stock valued at $498,367,000 after buying an additional 2,355,505 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of Merck & Co., Inc. by 9.1% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 24,733,151 shares of the company’s stock valued at $1,906,680,000 after acquiring an additional 2,063,255 shares during the last quarter. Finally, Mn Services Vermogensbeheer B.V. purchased a new position in Merck & Co., Inc. during the second quarter worth approximately $121,681,000. 71.83% of the stock is currently owned by institutional investors.
A number of analysts have recently commented on the company. Truist Securities started coverage on Merck & Co., Inc. in a report on Tuesday, July 27th. They set a “buy” rating and a $76.79 price objective for the company. Morgan Stanley downgraded Merck & Co., Inc. from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $90.00 to $85.00 in a report on Tuesday, September 7th. SVB Leerink increased their target price on shares of Merck & Co., Inc. from $99.00 to $101.00 and gave the stock an “outperform” rating in a research report on Friday, July 30th. Zacks Investment Research raised shares of Merck & Co., Inc. from a “sell” rating to a “hold” rating and set a $82.00 price target on the stock in a research report on Tuesday, August 24th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Merck & Co., Inc. from $105.00 to $100.00 and set an “overweight” rating for the company in a research note on Wednesday, June 9th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $91.09.
Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Wednesday, July 28th. The company reported $1.31 earnings per share for the quarter, meeting the consensus estimate of $1.31. Merck & Co., Inc. had a return on equity of 50.93% and a net margin of 11.48%. The company had revenue of $11.40 billion during the quarter, compared to the consensus estimate of $11.21 billion. During the same period last year, the firm earned $1.37 earnings per share. On average, analysts forecast that Merck & Co., Inc. will post 5.51 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 7th. Shareholders of record on Wednesday, September 15th will be issued a dividend of $0.65 per share. The ex-dividend date of this dividend is Tuesday, September 14th. This represents a $2.60 annualized dividend and a yield of 3.61%. Merck & Co., Inc.’s dividend payout ratio is presently 43.77%.
Merck & Co., Inc. Profile
Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Featured Article: What is an Initial Coin Offering (ICO)?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.